Pasithea Therapeutics’ VP will present PAS-004 at the CAGLA NeauxCancer Conference, discussing its potential in cancer treatment.
Quiver AI Summary
Pasithea Therapeutics Corp. announced that its Vice President of Business Development, Mathew Lazarus, will present at the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference from March 27-29, 2025, in New Orleans. His presentation will focus on PAS-004, a next-generation macrocyclic MEK inhibitor being developed for neurofibromatosis type 1 and other cancer treatments. Lazarus will share interim data from an ongoing Phase 1 study involving patients with advanced tumors driven by the MAPK pathway, highlighting the progress in clinical development. The conference aims to convene oncology professionals to discuss advancements in cancer care. Further details and information about the conference can be found on the CAGLA website.
Potential Positives
- Pasithea Therapeutics will have a prominent presence at the 2025 CAGLA NeauxCancer Conference, highlighting its commitment to advancing cancer treatment.
- The presentation by Mathew Lazarus will provide an opportunity to showcase interim safety and pharmacokinetic data for PAS-004, which may attract interest from potential investors and collaborators.
- The conference serves as a platform to engage with leading oncology researchers and industry executives, potentially enhancing networking and partnership opportunities for Pasithea.
Potential Negatives
- There is no mention of significant achievements or milestones regarding the development of PAS-004, which may raise concerns about the progress and effectiveness of the drug.
- The press release lacks specific data or results from the ongoing Phase 1 study, which could lead to skepticism regarding the safety and efficacy of PAS-004 among stakeholders.
- The focus on a presentation at a conference may imply that the company is relying on external exposure to bolster its credibility, rather than providing substantial updates on its development efforts.
FAQ
What is the CAGLA NeauxCancer Conference?
The CAGLA NeauxCancer Conference is a leading global forum focusing on advancements in oncology and cancer treatment.
When is the conference taking place?
The conference is scheduled for March 27-29, 2025, in New Orleans.
Who will be presenting at the conference?
Mathew Lazarus, Vice President of Business Development at Pasithea, will present on PAS-004 at the conference.
What will be discussed during the presentation?
The presentation will highlight interim safety, tolerability, and pharmacokinetic data from Pasithea’s ongoing Phase 1 study on PAS-004.
Where can I find more information about the conference?
You can visit https://cag-la.org/neauxcancer-2025/ for more details about the CAGLA NeauxCancer Conference.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KTTA Hedge Fund Activity
We have seen 3 institutional investors add shares of $KTTA stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 61,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $192,150
- ADAR1 CAPITAL MANAGEMENT, LLC removed 27,696 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $150,112
- UBS GROUP AG added 6,301 shares (+95.9%) to their portfolio in Q4 2024, for an estimated $19,848
- TOWER RESEARCH CAPITAL LLC (TRC) added 1,285 shares (+213.8%) to their portfolio in Q4 2024, for an estimated $4,047
- MORGAN STANLEY removed 500 shares (-33.3%) from their portfolio in Q4 2024, for an estimated $1,575
- FMR LLC removed 49 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $265
- BANK OF AMERICA CORP /DE/ removed 10 shares (-55.6%) from their portfolio in Q4 2024, for an estimated $31
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
-- Conference taking place on March 27-29, 2025 in New Orleans --
-- CAGLA NeauxCancer Conference is a leading global forum in oncology --
MIAMI, March 24, 2025 (GLOBE NEWSWIRE) --
Pasithea Therapeutics Corp.
(NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced its Vice President of Business Development, Mathew Lazarus, will be presenting at the 2025 Cancer Advocacy Group of Louisiana ("CAGLA") NeauxCancer Conference taking place on March 27-29, 2025 at the The Roosevelt Hotel in New Orleans.
Mr. Lazarus’s presentation will provide an overview of Pasithea’s next generation macrocyclic MEK inihibitor, PAS-004, including interim safety, tolerability and pharmacokinetic (PK) data from the Company’s ongoing open-label dose escalation Phase 1 study in advanced cancer patients with MAPK pathway-driven advanced tumors. He will discuss the Company's latest progress in clinical development and how Pasithea is advancing its next-generation molecule to transform cancer and NF1 treatment.
Details of the presentation are as follows:
Event: 2025 CAGLA NeauxCancer Conference
Date: March 28, 2025
Time: 11:00 AM CDT
Location: The Roosevelt New Orleans
Webcast: CAGLA 2025 Livestreams
The CAGLA NeauxCancer Conference is a premier gathering of leading oncology researchers, industry executives, and medical professionals focused on groundbreaking developments in cancer treatment and care.
For more information about the conference, visit
https://cag-la.org/neauxcancer-2025/
.
About Pasithea Therapeutics Corp.
Pasithea is a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. With an experienced team of experts in the fields of neuroscience, translational medicine, and drug development, Pasithea is developing new molecular entities for the treatment of neurological disorders, including Neurofibromatosis type 1 (NF1), Solid Tumors, and Amyotrophic Lateral Sclerosis (ALS). For more information, visit
www.pasithea.com
.
Pasithea Therapeutics Contact
Patrick Gaynes
Corporate Communications
pgaynes@pasithea.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
